WO2009056556A1 - 1,6-naphtyridines substituées en vue d'une utilisation en tant qu'inhibiteurs de scd - Google Patents

1,6-naphtyridines substituées en vue d'une utilisation en tant qu'inhibiteurs de scd Download PDF

Info

Publication number
WO2009056556A1
WO2009056556A1 PCT/EP2008/064635 EP2008064635W WO2009056556A1 WO 2009056556 A1 WO2009056556 A1 WO 2009056556A1 EP 2008064635 W EP2008064635 W EP 2008064635W WO 2009056556 A1 WO2009056556 A1 WO 2009056556A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
methyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/EP2008/064635
Other languages
English (en)
Inventor
Alain Claude-Marie Daugan
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of WO2009056556A1 publication Critical patent/WO2009056556A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a novel class of compounds believed to be inhibitors of stearoyl-CoA desaturase (SCD), compositions comprising said compounds, methods of synthesis and uses for such compounds in treating and/or preventing various diseases, including those mediated by SCD enzyme, such as diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, skin disorders such as acne, diseases or conditions related to cancer and the treatment of symptoms linked to the production of the amyloid plaque-forming A ⁇ 42 peptide such as Alzheimer's disease and the like.
  • SCD stearoyl-CoA desaturase
  • Acyl desaturase enzymes catalyze the formation of double bonds in fatty acids derived from either dietary sources or de novo synthesis in the liver. Mammals synthesise at least three fatty acid desaturases of differing chain length that specifically catalyze the addition of double bonds at the delta-9, delta-6, and delta-5 positions.
  • Stearoyl-CoA desaturases introduce a double bond in the C9-C10 position of saturated fatty acids.
  • the preferred substrates for the enzymes are palmitoyl-CoA (16:0) and stearoyl-CoA (18:0), which are converted to palmitoleoyl-CoA (16:1 ) and oleoyl-CoA (18:1 ), respectively.
  • the resulting mono-unsaturated fatty acids may then be employed in the preparation of phospholipids, triglycerides, and cholesteryl esters, in vivo.
  • SCD1 A number of mammalian SCD genes have been cloned. For example, two genes have been cloned from rats (SCD1 , SCD2) and four SCD genes have been isolated from mice (SCD1 , 2, 3 and 4). While the basic biochemical roles of SCD has been known in rats and mice since the 1970's (Jeffcoat, R et al., Elsevier Science (1984), VoI 4, pp. 85-1 12; de Antueno, RJ, Lipids (1993), Vol. 28, No. 4, pp. 285-290), it has only recently been directly implicated in human diseases processes.
  • SCD1 A single SCD gene, SCD1 , has been characterized in humans. SCD1 is described in Brownlie et al, WO 01/62954. A second human SCD isoform has been identified, and because it bears little sequence homology to known mouse or rat isoforms it has been named human SCD5 or hSCD5 (WO 02/26944).
  • inhibition of the activity of SCD in vivo can be used to ameliorate and/or treat one or more diseases such as dyslipidemia, hypoalphalipoproteinemia, hyperbetalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, atherosclerosis, obesity, Type I diabetes, Type Il diabetes, insulin resistance, hyperinsulinaemia, metabolic syndrome; other cardiovascular diseases e.g.
  • diseases such as dyslipidemia, hypoalphalipoproteinemia, hyperbetalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, atherosclerosis, obesity, Type I diabetes, Type Il diabetes, insulin resistance, hyperinsulinaemia, metabolic syndrome; other cardiovascular diseases e.g.
  • peripheral vascular disease reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, thrombosis; hepatic steatosis, non-alcoholic steatohepatitis (NASH) and other diseases related to accumulation of lipids in the liver.
  • NASH non-alcoholic steatohepatitis
  • An SCD-mediated disease or condition also includes a disorder of polyunsaturated fatty acid (PUFA) disorder, or a skin disorder, including but not limited to eczema, acne, psoriasis, skin ageing, keloid scar formation or prevention, diseases related to production or secretions from mucous membranes, such as monounsaturated fatty acids, wax esters, and the like (US2006/0205713A1 , WO2007/046868, WO2007/046867).
  • PUFA polyunsaturated fatty acid
  • SCD has been shown to play a physiological role in cholesterol homeostasis and the de novo biosynthesis of cholesterol esters, triglycerides and wax esters required for normal skin and eyelid function and therefore may be useful in the treatment of acne and other skin conditions (Makoto et al. J of Nutrition (2001 ), 131 (9), 2260-2268, Harrison et al. J of Investigative Dermatology (2007) 127(6), 1309-1317).
  • An SCD-mediated disease or condition also includes but is not limited to a disease or condition which is, or is related to cancer, neoplasia, malignancy, metastases, tumours (benign or malignant), carcinogenesis, hepatomas and the like (US2006/0205713A1 , WO2007/046868, WO2007/046867).
  • SCD- 1 has been identified as playing a role in human tumor cell survival and therefore has potential as an anticancer target (Morgan-Lappe et al. 2007 Cancer Res. 67(9) 4390-4398).
  • SCD inhibitors may also be useful for treating, delaying the onset of symptoms, or slowing the progression of symptoms of mild cognitive impairment (MCI), Alzheimer's Disease (AD), cerebral amyloid angiopathy (CAA) or dementia associated with Down Syndrome (DS) and other neurodegenerative diseases characterized by the formation or accumulation of amyloid plaques comprising A ⁇ 42 (US2007/0087363A1 ; Myriad Genetics).
  • MCI mild cognitive impairment
  • AD Alzheimer's Disease
  • CAA cerebral amyloid angiopathy
  • DS Down Syndrome
  • WO2005/01 1657 describes certain piperazine derivatives useful for inhibiting SCD activity.
  • the present invention provides a compound of formula (I) for inhibiting SCD activity:
  • X represents -CONH- or -NHCO-
  • R 1 represents:
  • N -C 6- ioaryl (such as phenyl or napthyl) optionally substituted by one, two or three groups independently selected from: (a) -Ci -6 alkyl (such as -CH 3 ), -Ci -6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -Ci -6 haloalkyl (such as -
  • -C 1-6 alkyl such as -CH 3
  • haloalkyl such as -CF 3
  • halogen such as chloro, bromo or fluoro
  • Y represents -CH 2 - or -OCH 2 -
  • W represents a -C 5- ioheteroaryl optionally substituted by one, two or three -Ci -6 alkyl (such as -CH 3 ) groups;
  • the said compounds have been found to inhibit SCD activity and may therefore be useful in the treatment of SCD-mediated diseases such as diseases or conditions caused by or associated with an abnormal plasma lipid profile including dyslipidemia, hypoalphalipoproteinemia, hyperbetalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, atherosclerosis, obesity, Type I diabetes, Type Il diabetes, insulin resistance, hyperinsulinaemia and metabolic syndrome; other cardiovascular diseases e.g.
  • peripheral vascular disease e.g., peripheral vascular disease, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, thrombosis, hepatic steatosis, nonalcoholic steatoheptatis (NASH) and other diseases related to accumulation of lipids in the liver; skin disorders e.g.
  • eczema eczema, acne, psoriasis, skin ageing, keloid scar formation or prevention, and diseases related to production or secretions from mucous membranes; cancer, neoplasia, malignancy, metastases, tumours (benign or malignant), carcinogenesis, hepatomas and the like; mild cognitive impairment (MCI), Alzheimer's Disease (AD), cerebral amyloid angiopathy (CAA) or dementia associated with Down Syndrome (DS) and other neurodegenerative diseases characterized by the formation or accumulation of amyloid plaques comprising A ⁇ 42.
  • MCI mild cognitive impairment
  • AD Alzheimer's Disease
  • CAA cerebral amyloid angiopathy
  • DS Down Syndrome
  • X represents -CONH-. In another aspect of the invention, X represents -NHCO-. In one aspect of the invention, R 1 represents: -C 6- ioaryl (such as phenyl or napthyl) optionally substituted by one, two or three groups independently selected from:
  • -Ci -6 alkyl such as -CH 3 ), -Ci -6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -Ci -6 haloalkyl (such as -CF 3 ), -Cs-ecycloalkyl, -OCi -6 haloalkyl (such as -OCF 3 ), -CN or halogen (such as chloro, bromo or fluoro),
  • -C 6 -ioaryl such as phenyl
  • -C 6 -ioaryl optionally substituted by one, two or three groups independently selected from: -C 1-6 alkyl (such as -CH 3 ), -Ci -6 alkoxy (such as -OCH 3 ), -Ci- 6 haloalkyl (such as -CF 3 ) or halogen (such as chloro, bromo or fluoro).
  • R 1 represents phenyl optionally substituted by one, two or three groups independently selected from:
  • -Ci -6 alkyl such as -CH 3 ), -Ci -6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -Ci -6 haloalkyl (such as -CF 3 ), -Cs-ecycloalkyl, -OCi -6 haloalkyl (such as -OCF 3 ), -CN or halogen (such as chloro, bromo or fluoro),
  • -Ci -6 alkyl such as -CH 3
  • -Ci -6 alkoxy such as -OCH 3
  • -Ci -6 haloalkyl such as -CF 3
  • halogen such as chloro, bromo or fluoro
  • R 1 represents -C 6 -ioaryl (such as phenyl) optionally substituted by one, two or three groups independently selected from: -C 1-6 alkyl (such as - CH 3 ), -Ci -6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -Ci -6 haloalkyl (such as -CF 3 ), -C 3- 6 cycloalkyl, -OCi -6 haloalkyl (such as -OCF 3 ), -CN or halogen.
  • -C 1-6 alkyl such as - CH 3
  • -Ci -6 alkoxy such as -OCH 3 or -OC 4 H 9
  • -Ci -6 haloalkyl such as -CF 3
  • -C 3- 6 cycloalkyl such as -OCi -6 haloalkyl (such as -OCF 3 ), -CN or halogen.
  • R 1 represents phenyl optionally substituted by one, two or three groups independently selected from: -Ci -6 alkyl (such as -CH 3 ), -Ci -6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -Ci -6 haloalkyl (such as -CF 3 ), -C 3-6 cycloalkyl, -OCi -6 haloalkyl (such as -OCF 3 ), -CN or halogen (such as chloro, bromo or fluoro).
  • -Ci -6 alkyl such as -CH 3
  • -Ci -6 alkoxy such as -OCH 3 or -OC 4 H 9
  • -Ci -6 haloalkyl such as -CF 3
  • -C 3-6 cycloalkyl such as -OCi -6 haloalkyl (such as -OCF 3 )
  • -CN or halogen such as chloro
  • R 1 represents phenyl optionally substituted by one or two groups independently selected from: -C 1-6 alkyl (such as -CH 3 ), -C 1-6 alkoxy (such as - OCH 3 or -OC 4 H 9 ), -C 1-6 haloalkyl (such as -CF 3 ), -C 3-6 cycloalkyl, -OC 1-6 haloalkyl (such as - OCF 3 ), -CN or halogen (such as chloro, bromo or fluoro).
  • -C 1-6 alkyl such as -CH 3
  • -C 1-6 alkoxy such as - OCH 3 or -OC 4 H 9
  • -C 1-6 haloalkyl such as -CF 3
  • -C 3-6 cycloalkyl such as -OC 1-6 haloalkyl (such as - OCF 3 )
  • -CN or halogen such as chloro, bromo or fluoro
  • R 1 represents phenyl optionally substituted by one, two or three groups independently selected from: -Ci -6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -Ci- 6 haloalkyl (such as -CF 3 ) or halogen (such as chloro, bromo or fluoro).
  • -Ci -6 alkoxy such as -OCH 3 or -OC 4 H 9
  • -Ci- 6 haloalkyl such as -CF 3
  • halogen such as chloro, bromo or fluoro
  • R 1 represents phenyl optionally substituted by one, two or three groups independently selected from: -Ci -6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -Ci- 3 haloalkyl (such as -CF 3 ) or halogen (such as chloro, bromo or fluoro).
  • R 1 represents phenyl optionally substituted by one or two groups independently selected from: -C 1-6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -C 1- 6 haloalkyl (such as -CF 3 ) or halogen (such as chloro, bromo or fluoro).
  • R 1 represents phenyl optionally substituted by one or two groups independently selected from: -Ci -6 alkoxy (such as -OCH 3 or -OC 4 H 9 ), -Ci- 3 haloalkyl (such as -CF 3 ) or halogen (such as chloro, bromo or fluoro).
  • R 1 represents phenyl optionally substituted by one, two or three groups independently selected from: -CF 3 , -OCH 2 CH(CH 3 ) 2 or halogen (such as chloro, bromo or fluoro).
  • R 1 represents phenyl optionally substituted by one or two groups independently selected from: -CF 3 , -OCH 2 CH(CH 3 ) 2 or halogen (such as chloro, bromo or fluoro).
  • R 1 is phenyl substituted in the meta position, that is in the 3 position, and the para position, that is in the 4 position, by halogen e.g chloro i.e.
  • Y represents -CH 2 -. In another aspect of the invention, Y represents -OCH 2 -.
  • W represents a -C 5- 6heteroaryl optionally substituted by one, two or three -Ci -6 alkyl (such as -CH 3 ) groups.
  • W represents a -C 5- 6heteroaryl optionally substituted by one or two -Ci -6 alkyl (such as -CH 3 ) groups.
  • W represents a -C 5- 6heteroaryl optionally substituted by -Ci -6 alkyl (such as -CH 3 ).
  • W represents a -C 5- 6heteroaryl optionally substituted by one, two or three -Ci -3 alkyl (such as -CH 3 ) groups.
  • W represents a -C 5- 6heteroaryl optionally substituted by one or two -Ci -3 alkyl (such as -CH 3 ) groups.
  • W represents a -C 5- 6heteroaryl optionally substituted by -Ci -3 alkyl (such as -CH 3 ). In another aspect of the invention, W represents a -C 5- 6heteroaryl optionally substituted by -CH 3 .
  • W represents a -C 5 heteroaryl optionally substituted by - C 1-3 alkyl (such as -CH 3 ).
  • W represents a -C 5 heteroaryl optionally substituted by - CH 3 .
  • W represents thiadiazole, triazole, pyrazole or thiazole optionally substituted by one, two or three -C 1-6 alkyl (such as -CH 3 ) groups.
  • W represents thiadiazole, triazole, pyrazole or thiazole optionally substituted by one, two or three -C 1-3 alkyl (such as -CH 3 ) groups.
  • W represents thiadiazole, triazole, pyrazole or thiazole optionally substituted by -CH 3 .
  • the invention provides a compound of formula (I) wherein X represents -NHCO- and Y represents -CH 2 -.
  • Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention.
  • the invention also extends to conformational isomers of compounds of formula (I) and any geometric ⁇ cis and/or trans) isomers of said compounds.
  • compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.
  • racemic compounds of formula (I) may be optionally resolved into their individual enantiomers. Such resolutions may conveniently be accomplished by standard methods known in the art. For example, a racemic compound of formula (I) may be resolved by chiral preparative HPLC.
  • alkyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms.
  • C 1-6 alkyl means a straight or branched alkyl containing at least 1 , and at most 6, carbon atoms.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n- hexyl, isobutyl, isopropyl, t-butyl and 1 ,1-dimethylpropyl.
  • alkyl may include alkylene, for example methylene (-CH 2 -), ethylene (- CH 2 CH 2 -) and propylene (-CH 2 CH 2 CH 2 -).
  • alkoxy refers to a straight or branched alkoxy group containing the specified number of carbon atoms.
  • C 1-6 alkoxy means a straight or branched alkoxy group containing at least 1 , and at most 6, carbon atoms.
  • alkoxy as used herein include, but are not limited to, methoxy, ethoxy, propoxy, prop-2- oxy, butoxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy and hexyloxy. The point of attachment may be on the oxygen or carbon atom.
  • halogen refers to a fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo) atom.
  • haloalkyl refers to an alkyl group having one or more carbon atoms and wherein at least one hydrogen atom is replaced with a halogen atom, for example a trifluoromethyl group and the like.
  • cycloalkyl refers to a saturated cyclic group containing 3 to 6 carbon ring-atoms. Examples include cyclopropyl, cyclopentyl and cyclohexyl.
  • cycloalkenyl refers to a partially unsaturated cyclic group containing 3 to 6 carbon ring-atoms. Examples include cyclobutenyl, cyclopentenyl, and cyclohexenyl.
  • C 5-1 oheteroaryl refers to an aromatic cyclic group containing 5 to 10 ring-atoms 1 , 2, 3 or 4 of which are hetero-atoms independently selected from nitrogen, oxygen and sulphur and the remaining ring-atoms are carbon, e.g. benzothiophenyl, indolyl or thienyl.
  • This definition includes both monocyclic and bicyclic ring systems and bicyclic structures at least a portion of which is aromatic and the other part is saturated, partially or fully unsaturated.
  • the term 'C 6- ioaryr means an aromatic carbocyclic moiety containing 6 to 10 carbon atoms.
  • the definition includes both monocyclic and bicyclic ring systems and bicyclic structures at least a portion of which is aromatic and the other part is saturated, partially or fully unsaturated.
  • aromatic, aryl groups include naphthyl, anthryl, phenanthryl, indanyl, indenyl, azulenyl, azulanyl, fluorenyl, phenyl and napthyl, and more specifically phenyl.
  • C 5-1 oheterocyclyr refers to a cyclic group containing 5 to 10 ring- atoms 1 , 2, 3 or 4 of which are hetero-atoms independently selected from nitrogen, oxygen and sulphur and the remaining ring-atoms are carbon, and, wherein said cyclic group is saturated, partially or fully unsaturated but, which is not aromatic e.g.
  • heterocyclyl and heteroaryl groups include: furyl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, dioxolanyl, oxazolyl, thiazolyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyranyl, pyridyl, piperidinyl, homopiperazinyl, dioxanyl, morpholino, dithianyl, thiomorpholino, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, sulfolanyl, tetrazolyl, triazinyl, azepinyl,
  • substituted refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
  • pharmaceutically acceptable means a compound which is suitable for pharmaceutical use.
  • Salts of compounds of formula (I) which are suitable for use in medicine are those wherein the counterion is pharmaceutically acceptable.
  • salts having non- pharmaceutically acceptable counterions are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of formula (I) and their pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, malic, mandelic, acetic, fumaric, glutamic, lactic, citric, tartaric, benzoic, benzenesulfonic, p-toluenesulfonic, methanesulfonic, ethanesulfonic or naphthalenesulfonic acid.
  • Other non-pharmaceutically acceptable salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. Reference is made to Berge et al. J. Pharm. ScL, 1977, 66, 1-19.
  • Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid.
  • the present invention includes within its scope all possible stoichiometric and non-stoichiometric forms thereof.
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent.
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • the solvent used is water and the solvate may also be referred to as a hydrate.
  • Solvates of compounds of formula (I) which are suitable for use in medicine are those wherein the solvent is pharmaceutically acceptable.
  • solvates having non- pharmaceutically acceptable solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of formula (I) and their pharmaceutically acceptable salts.
  • prodrug means a compound which is converted within the body, e.g. by hydrolysis, into its active form that has medical effects.
  • Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987 and in D. Fleishner, S. Ramon and H. Barba "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19(2) 1 15-130, each of which are incorporated herein by reference.
  • Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient.
  • Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved in vivo yielding the parent compound.
  • Prodrugs may include, for example, compounds of this invention wherein hydroxyl or amine groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy or amine groups.
  • representative examples of prodrugs include (but are not limited to) phosphonate, carbamate, acetate, formate and benzoate derivatives of hydroxy and amine functional groups of the compounds of formula (I)-
  • a compound, or a pharmaceutically acceptable salt thereof wherein the compound is selected from the group consisting of:
  • the compounds of the invention have been found to inhibit SCD activity and may therefore be useful in regulating lipid levels, e.g. plasma lipid levels.
  • Diseases or conditions caused by or associated with an abnormal plasma lipid profile and for the treatment of which the compounds of the invention may be useful include; dyslipidemia, hypoalphalipoproteinemia, hyperbetalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, atherosclerosis, obesity, Type I diabetes, Type Il diabetes, insulin resistance, hyperinsulinaemia and metabolic syndrome.
  • cardiovascular diseases for which the compounds of the present invention are useful include peripheral vascular disease, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes and thrombosis.
  • Other diseases or conditions include hepatic steatosis, non-alcoholic steatohepatitis (NASH) and other diseases related to accumulation of lipids in the liver.
  • NASH non-alcoholic steatohepatitis
  • the compounds of the invention may also be useful in the treatment of skin disorders e.g. eczema, acne, psoriasis, skin ageing, keloid scar formation or prevention, and diseases related to production or secretions from mucous membranes.
  • skin disorders e.g. eczema, acne, psoriasis, skin ageing, keloid scar formation or prevention, and diseases related to production or secretions from mucous membranes.
  • the compounds of the invention may also be useful in the treatment of cancer, neoplasia, malignancy, metastases, tumours (benign or malignant), carcinogenesis, hepatomas and the like.
  • the compounds of the invention may also be useful in the treatment of mild cognitive impairment (MCI), Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA) or dementia associated with Down Syndrome (DS) and other neurodegenerative diseases characterized by the formation or accumulation of amyloid plaques comprising A ⁇ 42.
  • MCI mild cognitive impairment
  • AD Alzheimer's disease
  • CAA cerebral amyloid angiopathy
  • DS dementia associated with Down Syndrome
  • other neurodegenerative diseases characterized by the formation or accumulation of amyloid plaques comprising A ⁇ 42.
  • the terms describing the indications used herein are classified in the Merck Manual of Diagnosis and Therapy, 17 th Edition and/or the International Classification of Diseases 10 th Edition (ICD-10).
  • ICD-10 International Classification of Diseases 10 th Edition
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in medical therapy.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating and/or preventing a disease or a condition susceptible to amelioration by an SCD inhibitor.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating and/or preventing acne, psoriasis, skin ageing, cancer, dyslipidemia, hypertriglyceridemia, atherosclerosis, obesity, Type Il diabetes, insulin resistance, hyperinsulinaemia, hepatic steatosis and/or non-alcoholic steatohepatitis (NASH).
  • NASH non-alcoholic steatohepatitis
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating and/or preventing acne, psoriasis, skin ageing, cancer, dyslipidemia, atherosclerosis, insulin resistance, hyperinsulinaemia, Type Il diabetes and/or hepatic steatosis.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating and/or preventing acne.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating and/or preventing a disease or a condition susceptible to amelioration by an SCD inhibitor in a mammal, including human.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating and/or preventing acne, psoriasis, skin ageing, cancer, dyslipidemia, hypertriglyceridemia, atherosclerosis, obesity, Type Il diabetes, insulin resistance, hyperinsulinaemia, hepatic steatosis and/or non-alcoholic steatohepatitis (NASH).
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating and/or preventing acne, psoriasis, skin ageing, cancer, dyslipidemia, hypertriglyceridemia, atherosclerosis, obesity, Type Il diabetes, insulin resistance, hyperinsulinaemia, hepatic steatosis and/or non-alcoholic steatohepatitis (NASH).
  • NASH non-alcoholic steatohepatitis
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating and/or preventing acne, psoriasis, skin ageing, cancer, dyslipidemia, atherosclerosis, insulin resistance, hyperinsulinaemia, Type Il diabetes and/or hepatic steatosis.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating and/or preventing acne.
  • the invention provides a method for treating and/or preventing a disease or a condition susceptible to amelioration by an SCD inhibitor, which method comprises administering to a subject, for example a mammal, including human, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides a method for treating and/or preventing acne, psoriasis, skin ageing, cancer, dyslipidemia, hypertriglyceridemia, atherosclerosis, obesity, Type Il diabetes, insulin resistance, hyperinsulinaemia, hepatic steatosis and/or non-alcoholic steatohepatitis (NASH), which method comprises administering to a subject, for example a mammal, including human, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • a subject for example a mammal, including human, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides a method for treating and/or preventing acne, psoriasis, skin ageing, cancer, dyslipidemia, atherosclerosis, insulin resistance, hyperinsulinaemia, Type Il diabetes and/or hepatic steatosis, which method comprises administering to a subject, for example a mammal, including human, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides a method for treating and/or preventing acne, which method comprises administering to a subject, for example a mammal, including human, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • treatment includes acute treatment or prophylaxis as well as the alleviation of established symptoms.
  • the compounds of the invention are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the invention.
  • final compounds of formula (I) can be converted into other compounds of formula (I) by techniques known to those in the art, for example, carboxylic acid substituents can be converted to esters or amides by routine techniques.
  • compounds of formula (I), wherein X represents -NHCO- (formula (Ia)) may be prepared according to reaction scheme 1 by reacting compounds of formula (III) and compounds of formula (IV), wherein P 1 represents a suitable nitrogen protecting group such as Boc, to form a compound of formula (II).
  • the reaction is suitably carried out in the presence of a coupling reagent such as HATU, EDCI and/or HOBt, in a suitable solvent such as DCM (suitably at room temperature to reflux) or DMF (suitably at room temperature to 80 0 C), and is followed by deprotection of compound of formula (II) under acidic conditions such as hydrochloric acid or trifluoracetic acid (suitably at room temperature).
  • the invention provides a process for the preparation of compounds of the formula (Ia) by reacting a compound of formula (III), wherein R 1 , Y and W are defined above, with a compound of formula (IV) wherein P 1 represents a suitable nitrogen protecting group, followed by the deprotection of a compound of formula (II).
  • the invention provides a process for the preparation of compounds of the formula (Ib) by reacting a compound of formula (Vl), wherein R 1 , Y and W are defined above, with a compound of formula (VII) wherein P 1 represents a suitable nitrogen protecting group, followed by the deprotection of a compound of formula (V),
  • Compounds of formula (XIII) may be prepared according to reaction scheme 6 by reacting compounds of formula (XV) with phthalic anhydride in a suitable solvent such as dioxane, followed by alkylation of compounds of formula (XIV) with a compound of formula (IX), wherein L 1 represents a suitable leaving group such as halogen or tosylate, in the presence of a base such as potassium carbonate in a suitable solvent such as acetonitrile (suitably at reflux temperature).
  • Compounds of formula (XXI) may be prepared according to reaction scheme 13 by reacting compounds of formula (XXII) with hydrazinecarbothioamide in the presence of a coupling reagent such as HATU, EDCI and/or HOBt, in a suitable solvent such as DMF (suitably at room temperature to 8O 0 C).
  • a coupling reagent such as HATU, EDCI and/or HOBt
  • a suitable solvent such as DMF (suitably at room temperature to 8O 0 C).
  • Compounds of formula (XXI) may also be prepared according to reaction scheme 13 by reacting compounds of formula (XXV) with hydrazinecarbothioamide with a base such as pyridine in a suitable solvent such as DMF (suitably at room temperature to reflux).
  • Compounds of formula (XXV) may be prepared by reacting compounds of formula (XXII) with a chlorinating agent such as oxalyl chloride or thionyl chloride in a suitable solvent such as dichloromethane (suitably at room temperature to reflux temperature).
  • a chlorinating agent such as oxalyl chloride or thionyl chloride
  • a suitable solvent such as dichloromethane (suitably at room temperature to reflux temperature).
  • Compounds of formula (XXII) may also be prepared according to reaction scheme 15 by reacting compounds of formula (XXIII) with a base such as sodium hydroxide in a suitable solvent such as water (suitably at room temperature to reflux temperature).
  • a base such as sodium hydroxide
  • a suitable solvent such as water (suitably at room temperature to reflux temperature).
  • Compounds of formula (XXVII) may be prepared according to reaction scheme 19, by reacting compounds of formula (VId) with thionyl chloride in chloroform at room temperature, followed by reaction with aqueous ammonia in acetonitrile (suitably at -5°C to 5 0 C).
  • Compounds of formula (XXXI), wherein L 1 represents bromine (formula (XXXIa)), may be prepared according to reaction scheme 21 by reacting compounds of formula (XXXII) with a brominating agent such as pyridium bromide in a suitable solvent such as THF suitably at 0 0 C or Bromine in a suitable solvent such as chloroform suitably at room temperature.
  • a brominating agent such as pyridium bromide in a suitable solvent such as THF suitably at 0 0 C or Bromine in a suitable solvent such as chloroform suitably at room temperature.
  • the resulting compound (XXXVIII) may react with an oxidation agent such as meta chloroperbenzoic acid in a suitable solvent such as dichloromethane suitably at 0°C to lead to compound (XXXVII).
  • the compound (XXXVII) may react with a cyanidation agent such as cyano trimethylsilane and dimethylcarbamic chloride in a suitable solvent such as dichloromethane suitably at room temperature to lead to compound (XXXVI).
  • the cyano group of compound (XXXVI) may be hydrolysed with acid such as concentrated HCI in a suitable solvent such as methyl alcohol suitably at 100 0 C to lead to compound (XXXV).
  • Compound of formula (IVa) may then be prepared from compound (XXXV) in the presence of tertbutyloxy carbonyl anhydride and a base such as sodium hydrogenocarbonate in a suitable solvent such as THF suitably at room temperature followed by reaction with aqueous base such as sodium hydroxide in a suitable solvent such as a mixture of THF and methyl alcohol suitably at reflux temperature.
  • XLVII 2-propynamide
  • XLVIII 2-propynamide
  • a suitable solvent such as toluene suitably at reflux temperature
  • the resulting compound (XLVI) may react with triflic anhydride in a presence of a base such as pyridine in suitable solvent such as dichloromethane suitably at 0 0 C to give the compound (XLV).
  • Compound (XLV) may react with carbon monoxide in the presence of a catalyst such as palladium diacetoxide, a ligand such as DPPP and a base such as diisopropylethylamine in a suitable solvent such as a mixture of methyl alcohol and THF (suitably at 70 0 C) to lead to compound (XLIV).
  • Compound (IVa) may be prepared by reacting compound (XLIV) with a base such as sodium hydroxide in a suitable solvent such as methanol and water (suitably at room temperature to reflux temperature).
  • Compounds of formula (VII), wherein P 1 represents a suitable nitrogen protecting group such as Boc (formula (Vila)), may be prepared according scheme 25 by palladium- catalyzed amination of compounds of formula (XLV) with 1 ,1-diphenylmethanimine in the presence of a catalyst such as palladium acetate, a ligand such as BINAP and a base such as cesium carbonate in a suitable solvent such as toluene suitably at reflux temperature. This is followed by cleavage of the imine intermediate with hydroxylamine hydrochloride and sodium acetate in a suitable solvent such as methanol at room temperature.
  • a catalyst such as palladium acetate, a ligand such as BINAP and a base such as cesium carbonate
  • a suitable solvent such as toluene suitably at reflux temperature.
  • the compounds of the invention may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1 ,000 compounds, and more preferably 10 to 100 compounds.
  • Libraries of compounds of the invention may be prepared by a combinatorial
  • a compound library comprising at least 2 compounds of the invention.
  • Suitable protecting groups for use according to the present invention are well known to those skilled in the art and may be used in a conventional manner. See, for example, "Protective groups in organic synthesis” by T.W. Greene and P. G. M. Wuts (John Wiley & sons 1991 ) or "Protecting Groups” by PJ. Kocienski (Georg Thieme Verlag 1994).
  • suitable amino protecting groups include acyl type protecting groups (e.g.
  • aromatic urethane type protecting groups e.g. benzyloxycarbonyl (Cbz) and substituted Cbz
  • aliphatic urethane protecting groups e.g. 9-fluorenylmethoxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl) and alkyl or aralkyl type protecting groups (e.g. benzyl, trityl, chlorotrityl).
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may also be used in combination with other therapeutic agents.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or pharmaceutically acceptable salt thereof together with one or more further therapeutic agent(s).
  • Compounds of the invention may be administered in combination with other therapeutic agents.
  • Preferred therapeutic agents are selected from the list: an inhibitor of cholesteryl ester transferase (CETP inhibitors), a HMG-CoA reductase inhibitor, a microsomal triglyceride transfer protein, a peroxisome proliferator-activated receptor activator (PPAR), a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an inhibitor of AcylCoA: cholesterol acyltransferase (ACAT inhibitor), a cannabinoid 1 antagonist and a bile acid sequestrant.
  • CETP inhibitors cholesteryl ester transferase
  • HMG-CoA reductase inhibitor HMG-CoA reductase inhibitor
  • PPAR peroxisome proliferator-activated receptor activator
  • a corticosteroid selected from the list: a corticosteroid, a vitamin D3 derivative, a retinoid, an immunomodulator, an anti androgen, a keratolytic agent, an anti-microbial, a platinum chemotherapeutic, an antimetabolite, hydroxyurea, a taxane, a mitotic disrupter, an anthracycline, dactinomycin, an alkylating agent and a cholinesterase inhibitor
  • each compound may differ from that when the compound is used alone.
  • Appropriate doses will be readily appreciated by those skilled in the art. It will be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian.
  • compositions comprising a combination as defined above together with at least one pharmaceutically acceptable carrier and/or excipient comprise a further aspect of the invention.
  • the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations by any convenient route.
  • either the SCD inhibitor or the second therapeutic agent may be administered first.
  • the combination may be administered either in the same or different pharmaceutical composition.
  • the two compounds When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately they may be provided in any convenient formulation, conveniently in such manner as are known for such compounds in the art.
  • the invention also includes a pharmaceutical composition comprising one or more compounds of formula (I) or pharmaceutically acceptable salt(s) in combination with one or more excipients.
  • the compounds of the invention may be administered in conventional dosage forms prepared by combining a compound of the invention with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the pharmaceutical compositions of the invention may be formulated for administration by any route, and include those in a form adapted for oral, topical or parenteral administration to mammals including humans.
  • compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.
  • Creams, lotions, or ointments may be prepared as rinse-off or leave-on products, as well as two stage treatment products for use with other skin cleansing or managing compositions.
  • the compositions can be administered as a rinse-off product in a higher concentration form, such as a gel, and then a leave-on product in a lower concentration to avoid irritation of the skin.
  • a rinse-off product in a higher concentration form, such as a gel
  • a leave-on product in a lower concentration to avoid irritation of the skin.
  • Ointments are hydrocarbon-based semisolid formulations containing dissolved or suspended drugs.
  • Creams and lotions are semi-solid emulsion systems and the term is applied both to water/oil or oil/water.
  • Gel formulations are semi-solid systems in which a liquid phase is trapped in a polymeric matrix.
  • the ointments may contain one or more hydrophobic carriers selected from, for example, white soft paraffin or other mineral waxes, liquid paraffin, non-mineral waxes, long chain alcohols, long chain acids and silicones.
  • the ointment may contain in addition to the hydrophobic carriers some hydrophillic carriers selected from, for example, propylene glycol and polyethylene glycol in combination with an appropriate surfactant/co-surfactant system.
  • the carrier compositions of the creams or lotions are typically based on water, white soft paraffin and an appropriate surfactant/co- surfactant system, in combination with other carriers/components selected from, for example, propylene glycol, butylene glycol glycerinemonostearate, PEG- glycerinemonostearate, esters such as Ci 2 -i5alkyl benzoate, liquid paraffin, non-mineral waxes, long chain alcohols, long chain acids silicones, non-silicone polymers.
  • an appropriate surfactant/co- surfactant system selected from, for example, propylene glycol, butylene glycol glycerinemonostearate, PEG- glycerinemonostearate, esters such as Ci 2 -i5alkyl benzoate, liquid paraffin, non-mineral waxes, long chain alcohols, long chain acids silicones, non-silicone polymers.
  • the gels may by way of example be formulated using isopropyl alcohol or ethyl alcohol, propylene glycol and water with a gelling agent such as hydroxyethyl cellulose, suitably in combination with minor components, for example one or more of butylene glycol and a wetting agent such as a poloxamer.
  • a gelling agent such as hydroxyethyl cellulose
  • An ointment, cream, lotion, gel, and the like can further comprise a moisturizing agent.
  • the moisturizing agent can be a hydrophobic moisturizing agent such as ceramide, borage oil, tocopherol, tocopherol linoleate, dimethicone or a mixture thereof or a hydrophilic moisturizing agent such as glycerine, hyaluronic acid, sodium peroxylinecarbolic acid, wheat protein, hair keratin amino acids, or a mixture thereof.
  • compositions according to the invention may also comprise conventional additives and adjuvants for dermatological applications, such as preservatives, acids or bases used as pH buffer excipients and antioxidants.
  • the present invention encompasses administration via a transdermal patch or other forms of transdermal administration.
  • Suitable formulations for transdermal administration are known in the art, and may be employed in the methods of the present invention.
  • suitable transdermal patch formulations for the administration of a pharmaceutical compound are described in, for example, U.S. Pat. No. 4, 460,372 to
  • a suitable transdermal patch for use in the methods of the present invention encompasses a suitable transdermal patch includes a backing layer which is non- permeable, a permeable surface layer, an adhesive layer substantially continuously coating the permeable surface layer, and a reservoir located or sandwiched between the backing layer and the permeable surface layer such that the backing layer extends around the sides of the reservoir and is joined to the permeable surface layer at the edges of the permeable surface layer.
  • the reservoir contains a compound of formula (I) or pharmaceutically acceptable salt thereof, alone or in combination, and is in fluid contact with the permeable surface layer.
  • the transdermal patch is adhered to the skin by the adhesive layer on the permeable surface layer, such that the permeable surface layer is in substantially continuous contact with the skin when the transdermal patch is adhered to the skin. While the transdermal patch is adhered to the skin of the subject, the compound of formula (I) or pharmaceutically acceptable salt thereof contained in the reservoir of the transdermal patch is transferred via the permeable surface layer, from the reservoir, through the adhesive layer, and to the skin of the patient.
  • the transdermal patch may optionally also include one or more penetration-enhancing agents in the reservoir that enhance the penetration of the compound of formula (I) or pharmaceutically acceptable salt thereof through the skin.
  • suitable materials which may comprise the backing layer are well known in the art of transdermal patch delivery, and any conventional backing layer material may be employed in the transdermal patch of the instant invention.
  • Suitable penetration-enhancing agents are well known in the art as well.
  • conventional penetration-enhancing agents include alkanols such as ethanol, hexanol, cyclohexanol, and the like, hydrocarbons such as hexane, cyclohexaue, isopropylbenzene; aldebydes and ketones such as cyclohexanone, acetamide, N, N- di(lower alkyl)acetamides such as N,N-diethylacetamide, N,N-dimethyl acetamide, N-(2- hydroxyethyl) acetamide, esters such as N,N-di-lower alkyl sulfoxides; essential oils such as propylene glycol, glycerine, glycerol monolaurate, isopropyl myristate, and ethyl oleate, salicylates, and mixtures of any of the above.
  • the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • suitable conventional carriers such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or
  • Preparations for oral administration may be suitably formulated to give controlled/extended release of the active compound.
  • Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.
  • fluid unit dosage forms are prepared utilising the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • the dry lyophilised powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active ingredient, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50 to 500 mg of the active ingredient.
  • the dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.
  • the optimal quantity and spacing of individual dosages of a compound of the invention will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of the invention given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • the invention also extends to novel intermediates disclosed herein, used in the preparation of compounds of formula (I) or salts thereof.
  • Analytical HPLC was conducted on a X-terra MS C18 column (2.5 ⁇ m 3 x 30 mm id) eluting with 0.01 M ammonium acetate in water (solvent A) and 100% acetonitrile using the following elution gradient: 0 to 4 minutes, 5 to 100%B; 4 to 5 minutes, 100%B at a flow- rate of 1.1 mL/min with a temperature of 40 0 C.
  • MS mass spectra
  • Analytical HPLC was conducted on an Uptisphere-hsc column (3 ⁇ m 30 x 3 mm id) eluting with 0,01 M ammonium acetate in water (solvent A) and 100% acetonitrile (solvent B) using the following elution gradient: 0 to 0.5 minutes, 5%B; 0.5 to 3.5 minutes, 5 to 100%B; 3.5 to 4 minutes, 100%B; 4 to 4.5 minutes, 100 to 5%B; 4.5 to 5.5 minutes, 5%B at a flow-rate of 1.3 mL/min with a temperature of 40 0 C.
  • MS mass spectra
  • Analytical method GC-MS Analytical GC was conducted on a DB-1 ms column (Agilent Technologies), 0.1 ⁇ m 10m x 0.1 mm id) eluting with an Helium flow of 0.5ml/min and pressure at 3.4 bar and with a gradient temperature: 0 to 0.35 min, 100 0 C; 0.35min to 6min, 100 0 C to 250°C (ramp of 80°C/min).
  • MS mass spectra
  • the mixture was poured into a mixture of ice and water (100 ml.) and extracted with
  • CDCI 3 ppm
  • reaction mixture was quenched with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate.
  • the combined organic extracts were dried over sodium sulfate, filtered, and evaporated to dryness.
  • the residue was purified by column chromatography eluting with petroleum ether/ethyl acetate: 5/1 to give the title compound (4.78 g, 23.5%).
  • Example 10 1-r(3.4-DichloroDhenyl)methyll-5-methyl- ⁇ /-(5.6.7.8-tetrahvdro-1.6- naphthyridin-2-yl)-1 H- 1 ,2,3-triazole-4-carboxamide hydrochloride
  • Example 11 1-r(3,4-Dichlorophenyl)methyll- ⁇ /-(5,6,7,8-tetrahvdro-1 ,6-naphthyridin-2-yl)- 1 H-pyrazole-4-carboxamide hydrochloride
  • Example 12 : /V- ⁇ 5-r(3.4-Dichlorophenvnmethyll-4-methyl-1.3-thiazol-2-yl ⁇ -5.6.7.8- tetrahvdro-1 ,6-naphthyridine-2-carboxamide hydrochloride
  • the compounds of the present invention may be analysed in vitro for SCD activity using an assay based on the production of [ 3 H]H 2 O, which is released during the enzyme- catalyzed generation of the monounsaturated fatty acyl CoA product.
  • the assay is performed in a 96-well filtration plates.
  • the titrated substrate used in the assay is the [9,10- 3 H] stearoyl Coenzyme A.
  • SCD-containing rat microsomes (2 ⁇ g protein) and substrate (1 ⁇ M) After incubation for 6 minutes of SCD-containing rat microsomes (2 ⁇ g protein) and substrate (1 ⁇ M), the labelled fatty acid acyl-CoA species and microsomes are absorbed with charcoal and separated from [ 3 H]H 2 O by centrifugation.
  • [ 3 H]H 2 O is used as a measure of SCD activity.
  • Compounds at concentrations starting at 10 ⁇ M to 0.1 nM or vehicle (DMSO) are preincubated for 5 minutes with the microsomes before addition of the substrate.
  • the concentration-responses are fitted with sigmoidal curves to obtain IC 50 values.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de tétrahydronaphtyridine (THN) substituée de formule (I) et leurs sels, des compositions pharmaceutiques les contenant et leur utilisation en médecine. En particulier, l'invention concerne des composés destinés à inhiber l'activité de SCD.
PCT/EP2008/064635 2007-10-31 2008-10-29 1,6-naphtyridines substituées en vue d'une utilisation en tant qu'inhibiteurs de scd WO2009056556A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0721419.0A GB0721419D0 (en) 2007-10-31 2007-10-31 Compounds
GB0721419.0 2007-10-31

Publications (1)

Publication Number Publication Date
WO2009056556A1 true WO2009056556A1 (fr) 2009-05-07

Family

ID=38834636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/064635 WO2009056556A1 (fr) 2007-10-31 2008-10-29 1,6-naphtyridines substituées en vue d'une utilisation en tant qu'inhibiteurs de scd

Country Status (2)

Country Link
GB (1) GB0721419D0 (fr)
WO (1) WO2009056556A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207204B2 (en) 2007-11-09 2012-06-26 Glaxosmithkline Llc Triazole derivatives as SCD inhibitors
WO2013056148A2 (fr) 2011-10-15 2013-04-18 Genentech, Inc. Procédés d'utilisation d'antagonistes de scd1
US8486977B2 (en) 2007-11-09 2013-07-16 Glaxosmithkline Llc 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors
CN104788450A (zh) * 2015-04-23 2015-07-22 湖南华腾制药有限公司 一种吡啶并哌嗪衍生物的制备方法
CN106366007A (zh) * 2016-08-30 2017-02-01 枣阳市福星化工有限公司 一种生产2‑氨基‑5‑氯二苯甲酮的方法
CN106478434A (zh) * 2016-08-30 2017-03-08 枣阳市福星化工有限公司 一种生产2‑甲氨基‑5‑氯二苯甲酮的方法
CN106478435A (zh) * 2016-08-30 2017-03-08 枣阳市福星化工有限公司 一种生产2‑甲氨基‑5‑氯二苯甲酮的方法
CN106496050A (zh) * 2016-08-30 2017-03-15 枣阳市福星化工有限公司 一种生产2‑氨基‑5‑氯二苯甲酮的方法
WO2018117196A1 (fr) 2016-12-20 2018-06-28 大日本住友製薬株式会社 Médicament ciblant une cellule souche cancéreuse
CN112312913A (zh) * 2018-03-23 2021-02-02 优曼尼蒂治疗公司 化合物和其用途
US10973810B2 (en) 2017-01-06 2021-04-13 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
WO2023231964A1 (fr) * 2022-05-30 2023-12-07 赛诺哈勃药业（成都）有限公司 Utilisation d'un dérivé de tétrahydronaphtyridine pour la préparation d'un médicament pour la prévention et le traitement de maladies liées à l'adhésion
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050124A1 (fr) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Derives fusionnes de piperidine et leurs utilisations en tant qu'agents therapeutiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050124A1 (fr) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Derives fusionnes de piperidine et leurs utilisations en tant qu'agents therapeutiques

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207204B2 (en) 2007-11-09 2012-06-26 Glaxosmithkline Llc Triazole derivatives as SCD inhibitors
US8486977B2 (en) 2007-11-09 2013-07-16 Glaxosmithkline Llc 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors
US9051281B2 (en) 2007-11-09 2015-06-09 Glaxosmithkline Llc Compounds
WO2013056148A2 (fr) 2011-10-15 2013-04-18 Genentech, Inc. Procédés d'utilisation d'antagonistes de scd1
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
CN104788450A (zh) * 2015-04-23 2015-07-22 湖南华腾制药有限公司 一种吡啶并哌嗪衍生物的制备方法
CN106478435A (zh) * 2016-08-30 2017-03-08 枣阳市福星化工有限公司 一种生产2‑甲氨基‑5‑氯二苯甲酮的方法
CN106478434A (zh) * 2016-08-30 2017-03-08 枣阳市福星化工有限公司 一种生产2‑甲氨基‑5‑氯二苯甲酮的方法
CN106366007A (zh) * 2016-08-30 2017-02-01 枣阳市福星化工有限公司 一种生产2‑氨基‑5‑氯二苯甲酮的方法
CN106496050A (zh) * 2016-08-30 2017-03-15 枣阳市福星化工有限公司 一种生产2‑氨基‑5‑氯二苯甲酮的方法
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2018117196A1 (fr) 2016-12-20 2018-06-28 大日本住友製薬株式会社 Médicament ciblant une cellule souche cancéreuse
US10973810B2 (en) 2017-01-06 2021-04-13 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
CN112312913A (zh) * 2018-03-23 2021-02-02 优曼尼蒂治疗公司 化合物和其用途
CN112312913B (zh) * 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
WO2023231964A1 (fr) * 2022-05-30 2023-12-07 赛诺哈勃药业（成都）有限公司 Utilisation d'un dérivé de tétrahydronaphtyridine pour la préparation d'un médicament pour la prévention et le traitement de maladies liées à l'adhésion

Also Published As

Publication number Publication date
GB0721419D0 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
WO2009056556A1 (fr) 1,6-naphtyridines substituées en vue d'une utilisation en tant qu'inhibiteurs de scd
EP2207774B1 (fr) Dérivés triazoles et inhibiteurs de scd
US20100120669A1 (en) Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
EP2144895A2 (fr) Composés
EP2368887B1 (fr) Dérivés de 1,2,3-triazole destinés à être utilisés comme inhibiteurs de la stéaroyl-coa désaturase
EP2099782A2 (fr) Carboxamides d'isoquinoline comme inhibiteurs de la stearoyl-coa desaturase
WO2009150196A1 (fr) Dérivés de n-thiazolyl-1, 2, 3, 4-tétrahydro-6-isoquinoline carboxamide comme inhibiteurs de la stéaroyle coa désaturase
WO2008074832A2 (fr) Composés
WO2009016216A1 (fr) Dérivés de triazole en tant qu'inhibiteurs de scd
US20100048617A1 (en) Compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08844127

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08844127

Country of ref document: EP

Kind code of ref document: A1